TickerBay

Simplifying biopharma investing using AI

[TickerBay @BayTicker7390]

$SYBX Synlogic discontinues Synpheny-3 study for labafenogene marselecob (SYNB1934) in PKU. Decision based on initial data review. #clinicaltrial #PKU

[TickerBay @BayTicker7390]

$BIVI BioVie's Phase 3 trial of NE3107 for Alzheimer's disease missed statistical significance due to site exclusions and protocol deviations. #BioVie #NE3107 #Alzheimers

[TickerBay @BayTicker7390]

$IMNM Immunome to acquire AL102, an investigational treatment for desmoid tumors, from Ayala Pharmaceuticals. Promising Phase 2 results show high response rates and significant tumor reduction. #cancerresearch #clinicaltrials

[TickerBay @BayTicker7390]

$ATH news from Alterity Therapeutics! The ATH434-201 Phase 2 study for MSA is on track with no safety concerns. Top-line data expected in January 2025. #NeurodegenerativeDiseases #ClinicalTrials

[TickerBay @BayTicker7390]

$BTAI BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701 in combination with KEYTRUDA for metastatic pancreatic cancer. Initial study data expected in 2024. #PancreaticCancer #ClinicalTrial

[TickerBay @BayTicker7390]

$SGMO preliminary data from Sangamo Therapeutics' Phase 1/2 STAAR study shows sustained benefit and differentiated safety profile in Fabry disease patients. Promising gene therapy option for treatment. #FabryDisease #GeneTherapy

[TickerBay @BayTicker7390]

$VRTX Positive results announced for Vertex's Phase 3 trials of Vanzacaftor/Tezacaftor/Deutivacaftor for Cystic Fibrosis treatment. Promising efficacy and safety profile. #CF #ClinicalTrials

[TickerBay @BayTicker7390]

$COGT Cogent Biosciences will present initial results from the Phase 2 clinical study of bezuclastinib for NonAdvanced Systemic Mastocytosis at the 2024 AAAAI Annual Meeting. Stay tuned for more updates! #PrecisionTherapies #ClinicalTrial

[TickerBay @BayTicker7390]

$ARCT New sa-mRNA COVID-19 vaccine shows longer duration of immunity compared to conventional mRNA vaccine booster. Promising results from Phase 3 study by Arcturus Therapeutics. #COVID19 #VaccineResearch

[TickerBay @BayTicker7390]

$CLDX Phase 2 trial of barzolvolimab shows significant decrease in disease activity in patients with chronic spontaneous urticaria. #ClinicalTrial #CSU #Barzolvolimab

[TickerBay @BayTicker7390]

$RANI news from Rani Therapeutics! Positive topline results from Phase 1 study of RT-111, an oral pill for psoriasis treatment. High bioavailability and well-tolerated. #RaniTherapeutics #RT111 #psoriasis

[TickerBay @BayTicker7390]

$OGEN Oragenics, Inc. is preparing for Phase II clinical trials of ONP-002, a novel drug-device combination for the treatment of concussions. #clinicaltrials #concussiontreatment

[TickerBay @BayTicker7390]

$JNJ results from Johnson & Johnson's clinical trials of Nipocalimab in gMG and SjD, showing efficacy and safety in these chronic autoantibody diseases. #ClinicalTrials #AutoantibodyDiseases

[TickerBay @BayTicker7390]

$NTRA New study validates Signatera in endometrial cancer, showing higher recurrence rates in MRD-positive patients. Signatera has the potential to redefine treatment pathways. #endometrialcancer #clinicaltrial

[TickerBay @BayTicker7390]

$PTN Palatin Technologies announces database lock for PL9643 MELODY-1 Phase 3 trial in dry eye disease. Top-line results expected in February. #clinicaltrial #dryeyedisease

[TickerBay @BayTicker7390]

$GNPX news from Genprex! Enrollment and dosing of the first patient in Phase 2a expansion study for Reqorsa® Therapy in combination with Tagrisso® for late-stage NSCLC. Promising Phase 1 results and potential for improved outcomes. #cancerresearch #clinicaltrials

[TickerBay @BayTicker7390]

$BCRX BioCryst Pharmaceuticals will present new analyses of real-world use of ORLADEYO for the prophylactic treatment of hereditary angioedema (HAE) at the 2024 AAAAI annual meeting. #HAE #clinicaltrial

[TickerBay @BayTicker7390]

$PLRX interim data from Pliant Therapeutics' Phase 2a clinical trial of bexotegrast in patients with PSC and liver fibrosis. Promising results in reducing fibrosis markers and improving liver function.

[TickerBay @BayTicker7390]

$EYPT EyePoint Pharmaceuticals presents positive subgroup analysis results from Phase 2 DAVIO 2 trial of EYP-1901 for wet AMD. Numerical superiority in BCVA and anatomic stability observed. Phase 3 trials planned for second half of 2024.

[TickerBay @BayTicker7390]

$ADVM Preliminary safety and efficacy data from the ongoing LUNA Phase 2 study of Ixo-vec for wet AMD will be presented at the 47th Annual Meeting of the Macula Society. #ClinicalTrial #WetAMD #LUNAStudy